PATENT ABSTRACTS 513

separate the areas stained by the receptor site op- tical enhancer and the nuclear area optical en- hancer. Measurements of the optical density values of the stained receptor areas yield an in- tensity value directly related to the quantity of hormonal receptor in the specimen. A com- parison of the nuclear area containing hormonal receptor with the total nuclear area yields a per- centage value which indicates the distribution of cells throughout of the specimen which contain receptor. These two values for intensity and dist- ribution are then combined to yield a predictive score for an assay. The measured score when compared to an empirically derived reference score is predictive of the prognosis of endocrine therapy.

5008186

D E T E C T I O N O F U N I Q U E C H L A M Y D I A S T R A I N

A S S O C I A T E D W I T H A C U T E R E S P I R A T O R Y D I S E A S E

J Thoma Grayston, Cho-chou Kuo, San-pin Wang assigned to The Board of Regents of the University of Washington

Methods for detecting a unique strain of chlamydia associated with acute respiratory dis- ease are disclosed. These methods utilize mono- clonal antibody directed against an antigenic determinant of the TWAR strain of chlamydia. Also disclosed is a method for determining the presence of antibodies to the TWAR strain, utilizing elementary bodies of the TWAR strain as antigen.

50O8196

S T I M U L A T I O N O F E N D O T H E L I A L C E L L G R O W T H

Daniel Connolly, Joseph Feder assigned to Monsanto Company

A method of stimulating endothelial cell growth is provided which comprises subjecting said cells to a growth stimulating amount of a highly purified vascular'permeability factor having the following characteristics: (a) it has a Mr about 34,000-40,000 as determined by sodium dodecylsulfate polyacrylamide gel elec- trophoresis; (b) it is a disulfide-linked protein dimer; (c) it has a N-terminal amino acid sequence as follows: See Patent for Chemical Structure 16PheMetAspVal20Tyr LysA rg- SerTyr 25CysArgProlleGlu30Met 31LeuValAsplle35PheGIn; and (d) it exhibits substantial mitogenic activity to endothelial cells in culture.

5008199

H Y B R I D O M A C E L L L I N E A N D M O N O C L O N A L A N T I B O D I E S T O T R E P O N E M A D E N T I C O L A A T C C

33520

Dou-Mei Wang, Linda D Sturdivant, Thomas A Biemer, Ronald Mink assigned to Warner- Lambert Company

Monoclonal antibody to Treponema denticola ATCC 33520 and a continuous cell line for its production is disclosed. These antibodies are particularly useful in immunoassays for detec- ting the presence of these microorganisms in the oral cavity.

5008187

A N T I F U N G A L F E R M E N T A T I O N P R O D U C T

5008241

N O V E L I N S U L I N P E P T I D E S

Louis Chaiet, Sheldon B Zimmerman, Richard L Monaghan, George Garrity assigned to Merck & Co Inc

Jan Markussen, Kjeld Norris, Liselott Langk- jaer, Herlev, Denmark assigned to Novo Nordisk A/S

A new antifungal agent which exhibits a moderately broad spectrum of activity towards filamentous fungi and also against Cryptococcus species of the yeast fungi, and which has been isolated from a solid stationary fermentation of an unidentified species of Fusarium is described.

insulin analogs characterized by amino acid residue at A21 other than Ash, with a resulting improvement in stability of insulin solutions at acid pH levels. Some insulin analogs may also have amino acid residue changes elsewhere so that these insulin analogs exhibit at least about

514 PATENT ABSTRACTS

one charge more than human insulin at a pH value of 7, with preferred substitutions being made for the glutamic acid residues at A4, A 17, B 13, B21 and/or a basic amino acid residue being substituted at B27. Also contemplated is op- tional blocking the C-terminal carboxyl group of the B-chain with an amido or ester residue.

The present invention relates to immunogenic preparations of peptides comprising amino acid sequences corresponding to antigenic deter- minants of the envelope glycoprotein of HIV, covalently coupled, directly or through a spacer molecule, to carrier molecules suitable for vac- cination of mammals.

5008371

B I O L O G I C A L L Y A C T I V E P O L Y P E P T I D E A N D U S E

T H E R E O F

Shunji Natori, Ibaragi, Japan assigned to Sanwa Kagaku Kenkyusho Co Ltd

A biologically active polypeptide, method of ob- taining same and use thereof are disclosed. The polypeptide is obtained through steps of cul- tivating a cell line established from Sarcophaga peregrina embryo to produce the same in a cul- ture medium, as product of the cell line, isolating and purifying the same. The polypeptide shows an anti-virus activity.

5 0 0 8 3 7 4

I L - I A L P H A D E R I V A T I V E S A N D D R U G S

~;a~or Nakai, Mayumi Kaneta. Yoshikazu Kikumoto, Yeong-Man Hong, Kazuyoshi Kawai, Setsuko Takegata, Kiyoshi lshii, Yasuo Yanagihara, Yoshikatsu Hirai, Tokushima, Japan assigned to Otsuka Pharmaceutical Co Lid

An interleukin-I alpha (IL-I alpha) derivative having a modified amino acid sequence of IL-I alpha, a gene coding for said derivative. medicinal composition comprising said deriva- tive as a pharmaceutically effective component and a medicinal use of homogeneous IL-I alpha.

5013548

P R O D U C T I O N O F A N T I B O D I E S T O H I V

Barton Haynes. Thomas Palker assigned to Duke University

5 0 1 3 ~ 9

P R O D U C T I O N , I S O L A T I O N , A N D I D E N T I F I C A T I O N O F N O V E L A N T I F U N G A L C O M P O U N D S

Alan R Putnam, Saroj Mishra, Muraleedharan Nair assigned to Board of Trustees Operating Michigan State University

A new species of Micromonospora, in particular Micromonospora spartanea A T C C 53803, is described. The species produces antifungal com- pounds spartanamicins A and B. Methods for the production, isolation and characterization of the compounds are described. The compounds contain deoxy-L-fucose, as well as another hex- ose and an amino sugar.

5 0 1 3 5 5 0

A N T I B I O T I C S C A L L E D C H L O R O P O L Y S P O R I N S B A N D C

, A P R O C E S S F O R T H E I R P R E P A R A T I O N , A N D T H E I R

T H E R A P E U T I C A N D V E T E R I N A R Y U S E

Tatsuo Hancishi, Takao Okazaki, Akio Torikata, Mutsuo Nakajima, Tokyo, Japan as- signed to Sankyo Company Limited

Novel compounds, called chloropolysporins B and C, and salts thereof have antibiotic pro- perties and would appear to be members of the class of glycopeptide antibiotics containing chlorine. They may be produced by cultivating a suitable strain of microorganism of the genus Micropolyspora, especially Micropolyspora sp. SANK 60983 (FERM BP-538). They may be combined with conventional pharmaceutically acceptable carriers or diluents for therapeutic use or incorporated into edible excipients, such as feed or water, fbr use as a growth-promoting agent, especially for farm animals.